Video is from the Shawn Ryan Show YouTube Channel, from February 20th, 2024. To visit this YouTube Channel, click here: https://www.youtube.com/@Shawn... Description: "Rick Doblin, Ph.D., is the Founder & President of the Multidisciplinary Association for Psychedelic Studies (MAPS) and this episode is all about his life and work. This episode is a holistic look at the point where traditional therapy meets psychedelics and how Doblin and his team have spent the last few decades appealing to the scientific community and lawmakers across the world.Doblin gives us a fresh perspective on the mental health crisis and discusses his studies & experiments in Iceland. We cover his early professional life and what lead him to pursue the science of alternative medicines. Doblin believes that with psychedelic assisted therapy, the world could be trauma free by 2070." To watch more videos from this YouTube channel, click here: https://www.youtube.com/@Shawn...

"In this episode of the Psychedelic Medicine Podcast, Hannah Cross, LCSW joins to discuss group ketamine assisted psychotherapy for frontline healthcare workers. Hannah is a licensed clinical social worker and therapist who specializes in trauma healing and psychedelic integration, including work on LSD and psilocybin clinical trials.  In this conversation, Hannah shares details from the study exploring group ketamine therapy in a cohort of ten frontline healthcare workers, discussing the study design, the intricacies of group therapy, and the specific dosing protocol and therapy regimen for the patients. She reveals the very promising results of this early study and also shares a number of emotional stories of transformation from the patients. In closing, Hannah discusses the early indicators of the durability of positive effects from this kind of ketamine assisted therapy and lists a number of additional on-going and upcoming studies of group ketamine treatments for other populations." Click Here to Listen to the Podcast

"In this episode of the Psychedelic Medicine Podcast, Kevin Franciotti, MA joins to discuss the intricacies of psychedelic-assisted therapies for substance use disorder. Kevin Franciotti is a Denver-based writer, therapist, advisor, and thought leader in the fields of psychology, psychedelics, and substance abuse counseling. In this conversation, Kevin shares his expertise on the existing research on psychedelic medicines for substance use disorder (SUD) and also discusses the limitations of the results of this research. He talks about the difficulties of designing trials and protocols for psychedelic therapies that target SUD, touching on how this disorder can interact with the neuro-physical and psychological effects of psychedelic medicines. He also contrasts emerging psychedelic treatments for SUD with dominant abstinence-based models and shares where he thinks psychedelic therapies may be a healthier alternative. In closing, Kevin reiterates that it is crucial to continue integrating harm reduction perspectives as psychedelic therapy continues to gain more mainstream traction." Click Here to Listen to the Podcast

"In this episode of the Psychedelic Medicine Podcast, Dr. Michelle Weiner joins to discuss the research on ketamine assisted psychotherapy for chronic pain conditions. Dr. Weiner is Double board-certified in Interventional Pain Medicine, Physical Medicine and Rehabilitation and the Director of Integrative Pain Management at Spine and Wellness Centers of America. She uses a unique personalized approach to treat the root cause of one's pain using a biopsychosocial model including lifestyle and plant medicine to empower her patients to cultivate health, optimize quality of life and decrease pharmaceuticals. In this conversation, Dr. Weiner discusses her recent research into ketamine therapy for chronic pain and comorbid depression, which compared psychedelic and psycholytic doses of the dissociative. She emphasizes the importance of a biopsychosocial approach to pain treatment and sees the psychotherapy aspect of the ketamine treatments as crucial to their efficacy, as this approach allows doctors to have a better understanding of the complex etiology of the patients pain beyond just what shows up on imaging and empowers patients to actively take ownership of their pain management. While the results from Dr. Weiner's study were very encouraging, she mentions that ketamine therapies typically require maintenance and that more longitudinal research is needed to further understand how durable these changes are. " Click Here to Listen to the Podcast

"In this episode of the Psychedelic Medicine Podcast, Nick Brüss, EdD, LMFT joins to discuss the possibilities of leveraging ketamine-assisted psychotherapy for accelerated growth. Dr. Brüss is a psychedelic therapist licensed in CA, NY and TX. He was a MAPS clinician and supervisor on the historic phase 3 MDMA for PTSD study, and is the director of psychedelic medicine advocacy for the TREAT California ballot initiative.  In this conversation, Dr. Brüss explains the intricacies of the internal family systems (IFS) model of therapy which he uses in conjunction with ketamine to help lead clients towards transformation and growth. Dr. Brüss explains how he helps clients work with their various "parts" both leading up to ketamine experiences and while they are under the influence of the dissociative, explaining how the ketamine experience helps to facilitate this work. He emphasizes the non-pathologizing, self-compassion focus of the IFS model and sees this as a natural fit for psychedelic-assisted work. In closing, Dr. Brüss shares details of the TREAT California ballot initiative, which has the potential to provide five billion USD in funding for research and affordable access to mental health treatments using psychedelic medicines."Click Here to Listen to this Podcast

"In this episode of "Intention to Treat," a study participant and a long-time investigator of hallucinogenic drugs for psychiatric conditions illuminate the effects of psilocybin in patients with depression."Click Here to Listen to this Podcast

Click Here to Access the Podcast

Author Michael Pollan leads the way in this docuseries exploring the history and uses of psychedelics, including LSD, psilocybin, MDMA and mescaline. Official trailer from the Netflix YouTube channel:Click Here to Watch

Podcast description from the Integrative Psychiatry Institute website: "Psychedelic therapy has proven to be one of the biggest breakthrough treatments in the mental health industry, especially for individuals with treatment-resistant conditions. Although the demand will continue to increase over the next few years, there won't be enough providers to meet that demand. Listen in as we discuss the current status of psychedelic therapy including Ketamine, MDMA & Psilocybin, and why now is a great time to get trained as a psychedelic-assisted therapy provider and understand the business of psychedelic therapy." Click Here to Listen to the Episode

This is the official trailer for a 2017 documentary titled "A New Understanding: the Science of Psilocybin". Documentary description from the Datun Center YouTube channel: "A New Understanding explores the treatment of end-of-life anxiety in terminally ill cancer patients using psilocybin, a psychoactive compound found in some mushrooms, to facilitate deeply spiritual experiences. The documentary explores the confluence of science and spirituality in the first psychedelic research studies with terminally ill patients since the 1970s."Click Here to Watch the Film

This is a trailer for a documentary titled "Neurons to Nirvana: The Great Medicines" from 2013. The full film can be viewed or rented from Amazon Video.Click Here to Watch the Full Film

"From Shock to Awe by Luc Côté and Janine Sagart is a documentary that tells the personal stories of two combat veterans suffering from severe trauma. Following their transformational journeys, they seek relief through psychedelics and abandon pharmaceuticals, revealing how these substances can be used to heal PTSD (Post-Traumatic Stress Disorder) for individuals and their families. Beyond the personal stories, this film also raises fundamental questions about the pharmaceutical industry, the US legal system and war."Click Here to Watch the Film

Description of documentary from PBS.org: "Hallucinogenic drugs-popularly called psychedelics-have been used by human societies for thousands of years. Today, scientists are taking a second look at many of these mind-altering substances - both natural and synthetic - and discovering that they can have profoundly positive clinical impacts, helping patients struggling with a range of afflictions from addiction to depression and PTSD."  Click Here to Watch the Documentary

Description from the Real Stories YouTube Channel: "Over two years we follow the first ever medical trial of psilocybin (the psychoactive ingredient in magic mushrooms) being used to treat a group of volunteers suffering from clinical depression. This remarkable film follows three volunteers and their families, and the ambitious staff running the trial, who are hoping this controversial treatment will have the power to transform millions of lives. With deeply moving footage of the 'trips' the patients go on, as well as interviews providing scientific and political context, this intimate film is an absorbing portrait of the human cost of depression, and the inspirational people contributing to groundbreaking psychedelic research."

Description from the Andrew Huberman YouTube Channel: "In this episode, my guest is Robin Carhart-Harris, PhD, distinguished professor of neurology and psychiatry at the University of California, San Francisco. He is one of leading researchers in the study of how psychedelics such as psilocybin, LSD and DMT can change the human brain and in doing so, be used to successfully treat various mental health challenges such as major depression, anorexia, obsessive-compulsive disorder (OCD) and addiction. He explains how psilocybin induces sustained changes in adaptive brain wiring and cognition. We discuss the key components of safe and effective psychedelic journeys, the role of hallucinations, the use of eye-masks to encourage people to "go internal," and music, as well as what effective therapist support consists of before, during and after the session (also known as integration). We discuss micodosing vs. macrodosing and how researchers control for placebo effects in psychedelic research. We also discuss the current legal landscape around psychedelic therapies. Psychedelic therapies are fast emerging as powerful and soon-to-be mainstream treatments for medical health disorders, but they are not without their risks. As such, this episode ought to be of use to anyone interested in brain plasticity, mental health, psychology or neuroscience." Click Here for a Full Playlist

Description from the Andrew Huberman YouTube Channel: "In this episode, I discuss methylenedioxymethamphetamine (MDMA), which is also commonly known as "ecstasy" or "molly," including how it works in the brain to cause short- and long- term-shifts in emotional processing and its clinical applications for the treatment of post-traumatic stress disorder (PTSD), alcohol and other substance-use addictions. I discuss the neuronal mechanisms for how MDMA elevates mood, empathy, motivation, social engagement, and reduces "threat detection" and how these effects can synergistically support talk therapy. I also explain the ongoing debate about the potential neurotoxicity of MDMA, myths about the origins and treatments for post-MDMA "crash," the evolving legal landscape around MDMA use for clinical purposes, and I caution recreational users about the extremely dangerous additives (e.g., fentanyl) now commonly found in black market MDMA. This should be of interest to those curious about MDMA, neuropharmacology, the origins of emotional processing in the brain, empathy, PTDS, neuroplasticity, mental health and psychiatry." Click Here for a Full Playlist

Description from the Andrew Huberman YouTube Channel: "In this episode, I discuss what psilocybin is (chemically) and how it works at the cellular and neural circuit level to trigger neuroplasticity, which is our brain's ability to rewire itself in ways that lead to long-lasting shifts in our emotional, cognitive and behavioral patterns and abilities. I discuss the emerging clinical trial evidence for the use of psilocybin in the treatment of depression, addictions and other psychiatric challenges. I explain the typical duration and phases of a psilocybin journey, the different categories of dosages often used and I explain the importance of set, setting and support when using psychedelics. I explain which groups of people place themselves at great risk by taking psilocybin as well as groups that could benefit, and I highlight the rapidly changing legal and medical landscape around psilocybin. This episode is a thorough exploration of psilocybin from the scientific and clinical literature perspective and ought to be of interest to anyone curious about psilocybin, mental health, neuroplasticity and/or psychedelics more generally."Click Here for a Full Playlist

This video is a small clip from when Rick Doblin, founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS), appeared on the Joe Rogan podcast in 2021. The full podcast is 3 hours and 15 minutes, and can be listened to by clicking the link below.Click Here to Listen to the Full Podcast

A new documentary series on Hulu titled "National Geographic Investigates" investigates how "After a decades-long prohibition, psychedelics are helping heal modern ills." This can be streamed directly from Hulu.

This is the trailer for a recent documentary series on Netflix from 2022. The title of the series is "How to Change Your Mind" and can be streamed directly from Netflix. Series description: "Author Michael Pollan leads the way in this docuseries exploring the history and uses of psychedelics, including LSD, psilocybin, MDMA and mescaline."

Description from the Tim Ferriss YouTube channel:"Dr. John Krystal is the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience, and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital.Dr. Krystal is a leading expert in the areas of alcoholism, post-traumatic stress disorder, schizophrenia, and depression. His work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine in depressed patients.ONE VERY IMPORTANT DISCLAIMER: I'm not a doctor, nor do I play one on the Internet. None of the content in this podcast constitutes medical advice or should be construed as a recommendation to use ketamine or psychedelics. There are psychological, physical, and sometimes legal risks with such usage. Please consult your doctor before considering anything we discuss in this episode."

Description from the APA YouTube channel: "Psilocybin, LSD and other psychedelic drugs were once considered promising treatments for depression, anxiety and other mental health ailments. Now, after a decades-long lull, researchers are once again looking into the therapeutic potential of these drugs. Roland Griffiths, PhD, a professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine, discusses new research on using psychedelics to treat depression, PTSD, and even alcohol and tobacco dependence."

From this podcast from Mindspace Well-Being: "As therapists and guides, we're holding that space for the location of healing to be intrinsic to that person." Click Here for a Full Library of Mindspace Well-Being Podcasts

From this podcast from Mindspace Well-Being: ""Psychedelics open things up and create opportunity. And integration is the work you do after to make sure you derive benefit from that experience." Click Here for a Full Library of Mindspace Well-Being Podcasts

From this podcast from Mindspace Well-Being: "The real medicine is the therapeutic relationship and psychedelics beautifully amplify that." Click Here for a Full Library of Mindspace Well-Being Podcasts

This podcast from the Mindspace Well-Being discusses the following: - How psychedelics differ from other psychiatric treatments and why they appear to be so effective- The role of psychotherapy in psychedelic treatments- The potential mechanisms in the therapeutic actions of psychedelic treatments- The importance of integration therapy after a psychedelic experience- How ketamine-assisted psychotherapy actually works Click Here for a Full Library of Mindspace Well-Being Podcasts

"Getting up-to-date on the research and practical application of psychedelic-assisted therapy is only half the story. Ketamine is a unique medicine in its bioactive properties for treating depression, but it can also produce a powerful psychedelic experience that can be leveraged with psychedelic-assisted therapy. In today's episode, Keith and Will discuss their personal experiences with ketamine-assisted psychotherapy in an intimate look at the power of this medicine, how to integrate both uplifting and very challenging experiences, and ways to start to get involved in the psychedelic-assisted therapy revolution."Click Here to Start Listening

With a full library of informative podcast episodes, "The mission of Plant Medicine.org and the Psychedelic Medicine Podcast is to demystify and de-stigmatize plant medicines by educating both the medical establishment and those who could potentially benefit from these medicines on the latest research and current best-practice administration of these substances."Click Here to Start Listening

"On this episode, Rick Doblin, founder and executive director of MAPS, discusses MDMA, a molecule that has (at a minimum) revolutionary therapeutic benefits for PTSD, but arguably could have, at the highest order, a lasting impact on humanity's ability to peacefully coexist."Click Here to Listen to the Podcast